(Press-News.org) HOUSTON -- Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer. The findings for each cohort were published today in The Lancet Oncology and The Lancet Diabetes & Endocrinology, respectively.
"Targeted therapies have dramatically improved care for patients with NSCLC and thyroid cancer driven by oncogenes, and the rapid clinical translation of selective RET inhibitor pralsetinib marks another milestone in a paradigm shift toward precision medicine," said principal investigator Vivek Subbiah, M.D., associate professor of Investigational Cancer Therapeutics.
The Food and Drug Administration approved pralsetinib for metastatic RET fusion-positive NSCLC in September 2020 and advanced RET-altered thyroid cancers in December 2020.
RET fusions occur when part of the DNA containing the RET gene breaks off and fuses with a different gene, which activates the kinase enzyme that continuously sends growth signals to the cell and drives cancer development. RET alterations are caused by a mutation in the DNA sequence and are oncogenic drivers in a variety of tumor types, most commonly in medullary thyroid cancers (approximately 90% of advanced cases), papillary thyroid cancers (approximately 10-20% of cases) and NSCLC (approximately 1-2% of cases).
Because standard cancer treatments -- including surgery, radiation, chemotherapy and immunotherapy -- have shown limited efficacy in patients with RET fusion-positive solid tumors, RET fusions have become an emerging target for novel therapies.
"Patients with RET-altered cancer are in need of personalized therapies," Subbiah said. "Based on this published data, pralsetinib shows durable responses in both the treatment-naïve and treatment-refractory settings in RET-positive NSCLC and thyroid cancer, providing evidence that this drug can be an option as a new standard of care for patients with this rare cancer."
In the NSCLC cohort, the analysis included 233 patients with RET fusion-positive NSCLC, as of a data cutoff of May 22, 2020. Ninety-two patients previously received platinum-based chemotherapy and 29 had no prior systemic treatment. The findings showed that pralsetinib achieved an overall response rate (ORR) of 70% and a complete response rate of 11% in patients with no prior systemic treatment, and a 61% ORR and 6% complete response rate in patients who previously received platinum-based chemotherapy.
In the thyroid arm of the study, researchers enrolled patients with RET-altered locally advanced/metastatic solid tumors, including 122 patients with RET-mutant medullary thyroid cancer and 20 patients with RET fusion-positive thyroid cancers, as of a data cutoff of May 22, 2020. The ORR was 71% in patients with treatment-naïve RET-mutant medullary thyroid cancer, 60% in patients previously treated with cabozantinib and/or vandetanib and 89% in patients with RET fusion-positive thyroid cancer.
"Until 2020, standard approved therapies for advanced thyroid cancer included multikinase inhibitors, which are effective but associated with a broad spectrum of potentially dose-limiting adverse effects," said trial co-investigator Mimi Hu, M.D., professor of Endocrine Neoplasia and Hormonal Disorders. "The highly potent RET-inhibitors, such as pralsetinib, led to a high response rate and have a more tolerable side-effect profile, thus improving patient satisfaction. Development of novel precision therapies is essential for our patients with this rare disease."
Five thyroid cancer patients (4%) discontinued therapy due to treatment-related adverse events (TRAEs), one patient died due to a TRAE and 14 NSCLC patients (6%) discontinued treatment due to TRAEs. Ultimately, the results showed that pralsetinib was a potent yet well-tolerated treatment for patients with RET fusion-positive NSCLC and RET-altered thyroid cancer.
"These data reiterate the importance of continued clinical implementation of genomic testing to identify actionable oncogenic drivers that include RET alterations," Subbiah said.
Blueprint Medicines Corporation funded the ARROW study. A full list of co-authors and their disclosures can be found in The Lancet Oncology and The Lancet Diabetes & Endocrinology papers.
INFORMATION:
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No. 1 for cancer care in U.S. News & World Report's "Best Hospitals" survey. It has ranked as one of the nation's top two hospitals for cancer care since the survey began in 1990 and has ranked first 15 times in the last 18 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
The moons of planets that have no parent star can possess an atmosphere and retain liquid water. Astrophysicists at LMU have calculated that such systems could harbor sufficient water to make life possible - and sustain it.
Water - in liquid form - is the elixir of life. It made life possible on Earth and is indispensable for the continuing existence of living systems on the planet. This explains why scientists are constantly on the lookout for evidence of water on other solid bodies in the Universe. Up to now, however, the existence of liquid water on planets other than Earth has not been directly proven. However, ...
The increased use of ridesharing apps was linked to a decrease in motor vehicle collisions and impaired driving convictions in Houston, according to published research by The University of Texas Health Science Center at Houston (UTHealth).
The findings were published today in JAMA Surgery.
Christopher Conner, MD, PhD, neurosurgery resident in the Vivian L. Smith Department of Neurosurgery at McGovern Medical School at UTHealth and the study's lead author, said the research is timely as more individuals are utilizing ridesharing apps.
"Automobile accidents are the leading cause of death and disability among young people, so anything we can do to reduce those incidents ...
Prostate cancer is the second most common cancer among men, according to the American Cancer Society. It's also one of the trickiest cancers to diagnose and treat.
But new research from the University of Georgia has identified a protein that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
"Unfortunately, prostate cancer that has spread to the bone is very aggressive, often lethal and very difficult to treat," said Brian Cummings, corresponding author of the study and head of the College of Pharmacy's pharmaceutical and biomedical sciences department. "Even in cases of successful treatment, the patient's quality of life is severely lessened due to bone loss."
Prostate cancer that hasn't spread beyond nearby ...
There are still many unsolved mysteries about the human brain and its development. Now, a novel study published in Frontiers in Psychiatry sheds new light on the neurobiological origins of our individual traits.
Functional connectivity is the coordinated activity - activation or deactivation - through time between separate brain regions, regardless of their physical closeness or the type of neural connections between them. Changes in functional connectivity can be a sign of mental health disorders such as depression, eating disorders, and schizophrenia, and are thought to have developmental origins.
We know that mental health is characterized by three functional brain networks. The first is hypoconnectivity ...
People who have a high sensation-seeking personality trait may be more likely to develop an addiction to cocaine, according to a Rutgers study.
"Although many people try illicit drugs like cocaine or heroin, only a small proportion develop an addiction," said lead author Morgan James, a member of the Rutgers Brain Health Institute and an assistant professor in the department of psychiatry at Rutgers Robert Wood Johnson Medical School. "The interaction found between sensation-seeking traits and the drug-taking experience show that predisposition to addiction has a genetic basis, and that this interacts with environmental factors such as patterns of drug use. The sensation-seeking trait was predictive of rats' likelihood to exhibit stronger ...
For older adults, participating in social activities can protect against physical and mental signs of aging, but it may also pose risks, especially for women.
A new analysis of national data led by UC San Francisco found that older women who were broadly engaged in social activities before the COVID pandemic had 76 percent higher odds of experiencing emotional abuse or mistreatment than women who were less engaged.
The paper is published June 9, 2021 in the Journal of the American Geriatrics Society.
"Given widespread discussion about the negative effects of social isolation of ...
Research from the University of Washington shows that endangered blue whales are present and singing off the southwest coast of India. The results suggest that conservation measures should include this region, which is considering expanding tourism.
Analysis of recordings from late 2018 to early 2020 in Lakshadweep, an archipelago of 36 low-lying islands west of the Indian state of Kerala, detected whales with a peak activity in April and May.
The study was published in May in the journal Marine Mammal Science.
"The presence of blue whales in Indian waters is well known from several strandings and some live sightings of blue whales," said lead author Divya Panicker, a ...
A new study conducted by the researchers at the University of Liverpool reveals how the ancient photosynthetic organisms - cyanobacteria - evolve their photosynthetic machinery and organise their photosynthetic membrane architecture for the efficient capture of solar light and energy transduction.
Oxygenic photosynthesis, carried out by plants, algae, and cyanobacteria, produces energy and oxygen for life on Earth and is arguably the most important biological process. Cyanobacteria are among the earliest phototrophs that can perform oxygenic photosynthesis and make significant contributions to the Earth's atmosphere and primary production.
Light-dependent photosynthetic reactions are performed by a set of photosynthetic ...
Laser-produced high energy density plasmas, akin to those found in stars, nuclear explosions, and the core of giant planets, may be the most extreme state of matter created on Earth. Now scientists at the U.S. Department of Energy's (DOE) Princeton Plasma Physics Laboratory (PPPL), building on nearly a decade of collaboration with the National Ignition Facility (NIF) at the DOE's Lawrence Livermore National Laboratory (LLNL), have designed a novel X-ray crystal spectrometer to provide high-resolution measurements of a challenging feature of NIF-produced HED plasmas.
Most powerful lasers
The ...
An international research team led by members from the Technical University of Munich, the Deutsches Museum, Munich, and the Swedish Linköping University has developed a method to manufacture two-dimensional polymers with the thickness of a single molecule. The polymers are formed on a surface by the action of light. The discovery paves the way to new ultrathin and functional materials.
The quest for new two-dimensional materials has rapidly intensified after the discovery of graphene - a supermaterial whose excellent properties include high conductivity and strength, making it incredibly versatile.
Two main ...
